Progress with regenerative medicine is supporting the development of a new type of asthma treatment that has the potential to reduce asthma attacks and repair lung damage.
In this article:
Therapeutic Applications of Umbilical Cord Blood & Tissue Proliferate in 2026
Cancer treatment using very high-dose chemotherapy or radiation therapy often results in severe injury to a patient’s blood-forming cells, called their hematopoietic (“blood formation”) system. Therefore, radiation therapy is soon followed by hematopoietic stem cell transplantation (HSCT), which is a method of reconstructing a patient’s blood system that has been destroyed by cancer treatment. Cord blood can also be used as a source of stem cells for hematopoietic stem cell transplantation (HSCT), providing an important alternative to the traditional options of peripheral blood and bone marrow transplant. Importantly, bone marrow and peripheral blood require full tissue matching for use in HSCT, while umbilical cord blood only requires partial matching. [Read more…]
Applied StemCell Demonstrates Efficient Knock-In of a 50 kb DNA Construct into Human iPSCs Using TARGATT™ Technology
MILPITAS, Calif., Nov. 11, 2025 – Applied StemCell, Inc. (ASC), today announced the successful knock-in of a 50 kilobase (kb) multifunctional DNA insert into human induced pluripotent stem cells (iPSCs) using its proprietary TARGATT™ technology. The achievement establishes a new benchmark for the size and complexity of genetic payloads that can be efficiently and site-specifically integrated into the human genome. [Read more…]
Vector BioMed Expands LENTIVERSE™ Platform and Unveils New Brand Identity to Close the Gap Between CGT Innovation and Patient Access
The expansion of LENTIVERSE™ platform introduces “One Lentiviral Vector Platform, Two Paths to Advance Cures,” aligning scientific rigor with transparent economics and global accessibility.
GAITHERSBURG, Md., Nov. 6, 2025 — Vector BioMed, a leading lentiviral vector supplier and contract vector development and manufacturing organization (CVDMO), today announced the expansion of its LENTIVERSE™ platform alongside the unveiling of its new brand identity, designed to accelerate global gene therapy access by providing custom and ready-to-deploy solutions. This expansion strengthens the company’s mission to make gene therapies more accessible and cost-effective for patients worldwide. [Read more…]
Bridging the Gap: Streamlining iPSC-Derived Cell Line Development from Donor Cells to MCB
Allogeneic iPSC-derived therapies hold immense promise, offering scalable, off-the-shelf solutions for a wide spectrum of diseases. However, the journey from donor cells to a gene edited, clinically compliant GMP Master Cell Bank (MCB) is fraught with challenges and is particularly vulnerable to risks stemming from misaligned early development.
A major bottleneck seen in the majority of iPSC therapeutic programs arises when development teams continue to rely on R&D grade cell lines to confirm proof-of-concept, conduct preclinical animal studies, and to start process & analytical development. [Read more…]
- « Previous Page
- 1
- …
- 39
- 40
- 41
- 42
- 43
- …
- 339
- Next Page »